Brusatol may serve as potential adjuvant therapy for pancreatic ductal adenocarcinoma

Announcing a new publication for Acta Materia Medica journal. Chemoresistance to gemcitabine (Gem) remains a substantial obstacle in the treatment of pancreatic ductal adenocarcinoma carcinoma (PDAC).

from News Medical Medical Research News Feed https://ift.tt/o6tD1Gw